Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Pfizer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Turning Point Therapeutics, Inc.
Revolution Medicines, Inc.
University of Edinburgh
Second Life Therapeutics
Novartis
Revolution Medicines, Inc.
Lund University Hospital
Pfizer
Purdue University
Hoffmann-La Roche
New Day Diagnostics
Thomas Jefferson University
National Cancer Center Hospital East
Imperial College London
Magentiq Eye LTD
University of Aarhus
Leiden University Medical Center
Kyowa Kirin Co., Ltd.
University Hospital, Antwerp
Shandong Provincial Hospital
Catalysis SL
Sumitomo Pharma America, Inc.
Fujian Cancer Hospital
RenJi Hospital
Hoffmann-La Roche
Fudan University
RenJi Hospital
RenJi Hospital
Sociedad Española de Medicina Nuclear e Imagen Molecular
St George's, University of London
RenJi Hospital
RenJi Hospital
Zhejiang University
Magentiq Eye LTD
State Scientific Centre of Coloproctology, Russian Federation
Asociación Española de Gastroenterología
Novartis
Fudan University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AbbVie
Zhejiang University
Isofol Medical AB
National and Kapodistrian University of Athens
Isofol Medical AB
Isofol Medical AB
Lund University Hospital
LEO Pharma